Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210389 | 1.00 | MMP2 (0.60) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL5212208 | 1.00 | MMP2 (0.60) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL5212809 | 0.88 | MMP2 (0.53) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL5210516 | 0.84 | LMNA (0.53) | MMP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5211899 | 0.84 | LMNA (0.53) | MMP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5210506 | 0.84 | LMNA (0.53) | MMP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4953709 | 0.81 | ESR1 (0.52) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL4953698 | 0.81 | ESR1 (0.52) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL5211073 | 0.81 | ESR1 (0.52) | MMP2ESR1PSEN1PSEN2APH1B | |
| SCHEMBL5215097 | 0.81 | ESR1 (0.46) | MMP2ESR1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304073-B2 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2007-12-04 | — | — | US | claimed |
| EP-1567502-B1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH CORP (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| US-6894061-B2 | Substituted dihydrophenanthridinesulfonamides | WYETH (US) | 2005-05-17 | — | — | US | claimed |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | WYETH | 2004-08-26 | — | — | US | claimed |
| EP-1567502-B1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1567502-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | Wyeth (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6894061-B2 | Substituted dihydrophenanthridinesulfonamides | WYETH (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | WYETH | 2004-08-26 | — | — | US | disclosed |
| WO-2004050631-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | MMP2 1120/4885ESR1 19/4885PSEN1 3841/4885 |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | TNNT2, TNNI3, SIRT5 | MMP2 1176/4885ESR1 4598/4885PSEN1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.